“

In an ideal world, you want to take a 78-year-old and say, I think in your brain amyloid is contributing to 20 percent of your cognitive problems, so I’ll give you an anti-amyloid therapy. You also have tau proteins contributing to about 35 percent of your problems, and so on, you’d want to design a therapeutic regimen based on the different components and their contributions to that patient’s disease.